

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Raman K. Bakshi et al.



Serial No. 10/526,178

Filed: February 28, 2005

For: PIPERAZINE UREA DERIVATIVES AS
MELANOCORTIN-4 RECEPTOR AGONISTS

Art Unit: _____

Examiner: _____

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450J
INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By David R. Brown Date 5/27/05

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: BAERBEL R. BROWN

Attorney _____ For Applicant(s)

Reg. No. 36,502

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-0672

Date: 5/27/05

COMPLETE IF KNOWN

(use as many sheets as necessary)

Sheet

1

of

3

Attorney Docket Number

21140YP

Application Number

10/526,178

Filing Date

February 28, 2005

First Named Inventor

Raman K. Bakshi et al.

Group Art Unit

Examiner Name

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
			WO 99/64002	Merck & Co., Inc.	12/16/1999
			WO 01/91752	Merck & Co., Inc.	12/06/2001
			WO 01/70708	Merck & Co., Inc.	09/27/2001
			WO 01/70337	Merck & Co., Inc.	09/27/2001
			WO 00/74649	Merck & Co., Inc.	12/14/2000
			WO 96/35713	Pfizer, Inc.	11/14/1996
			WO 03/009847	Amgen, Inc.	02/06/2003
			WO 02/068387	Merck & Co., Inc.	09/06/2002
			WO 02/070511	Bristol-Myers Squibb Company	09/12/2002
			WO 96/38471	Pfizer, Inc.	12/05/1996

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

(use as many sheets as necessary)

Sheet

2

of

3

COMPLETE IF KNOWN

Application Number

10/526,178

Filing Date

February 28, 2005

First Named Inventor

Raman K. Bakshi et al.

Group Art Unit

Examiner Name

Attorney Docket Number

21140YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
			WO 02/15909		Merck & Co., Inc.	02/28/2002
			WO 02/059095		Eli Lilly and Company	08/01/2002
			WO 02/059107		Eli Lilly and Company	08/01/2002
			WO 02/059108		Eli Lilly and Company	08/01/2002
			WO 02/059117		Eli Lilly and Company	08/01/2002
			WO 02/068388		Merck & Co., Inc.	09/06/2002
			WO 03/007949		Merck & Co., Inc.	01/30/2003
			WO 03/031410		Neurocrine Biosciences, Inc.	04/17/2003
			WO 01/58891		Vertex Pharmaceuticals Incorporated	08/16/2001
			WO 99/09984		Merck & Co., Inc.	03/04/1999

Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/526,178
Filing Date	February 28, 2005
First Named Inventor	Raman K. Bakshi et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21140YP

3

of

3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Wessells et al., J. of Urology, Vol. 160(2), (1998), pp. 389-393, "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction..."
	AB	Giraud et al., Brain Research, Vol. 809 (1998), pp. 302-306, "Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands"
	AC	Chen et al., Cell, Vol. 91 (1997), pp. 789-798, "Exocrine gland dysfunction in MC5-R-deficient mice: ..."
	AD	Chaki et al., Exp. Opin. Ther. Patents (2001), Vol. 11(11), pp. 1677-1692, "Recent advances in feeding suppressing agents: Potential therapeutic strategy for the treatment of obesity"
	AE	Dorr et al., Life Sciences, Vol. 58 (1996), pp. 1777-1784, "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study"
	AF	Kask et al., Biochem. & Biophys. Res. Comm., Vol. 245 (1998), pp. 90-93, "Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats"
	AG	Huszar et al., Cell, Vol. 88 (1997), pp. 131-141, "Targeted disruption of the melanocortin-4 receptor results in obesity in mice"
	AH	Wikberg et al., Pharma., Vol. 42 (2000), pp. 393-420, "New aspects on the melanocortins and their receptors"
	AI	Wikberg et al., Exp. Op. Ther. Patents, Vol. 11 (2001), pp. 61-76, "Melanocortin receptors: New opportunities in drug discovery"
	AJ	Andersson, Exp. Op. Ther. Patents, Vol. 11 (2001), pp. 1583-1592, "Ligands to the melanocortin receptors"
	AK	Peptides: Frontiers of Peptide Science, Fifteenth American Peptide Symposium, June 14-19, 1997 (Nashville, TN)
	AL	Corcos et al., Society for Neuroscience, Vol. 23 (1997), Abstract 267.9, "HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats"
	AM	Marsh, Nat. Genet., Vol. 21 (1999), pp. 119-122, "Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides"

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003